JAGX · XBRL financial data
Jaguar Health financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (JAGX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 9,385 | 4,335 | 11,956 | 9,761 | 11,689 | 11,511 |
| Cost of revenue | 3,280 | 2,333 | 2,019 | 2,037 | 1,955 | 3,774 |
| Cost of goods and services sold | — | — | — | — | — | 97 |
| Research and development | 6,413 | 15,079 | 17,647 | 18,596 | 16,542 | 24,966 |
| General and administrative | 14,387 | 17,103 | 17,868 | 16,588 | 16,331 | 18,644 |
| Operating income (loss) | (26,647) | (40,708) | (34,415) | (34,291) | (30,831) | (45,908) |
| Interest expense | 2,792 | 8,421 | 12,723 | 6,382 | 231 | 67 |
| Other income (expense) | 190 | (765) | 950 | 200 | 51 | 43 |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (33,809) | (53) | (48) | (41,300) | (39) | (53,575) |
| Earnings per share, basic‡ USD per share | (10,578,650,489.17) | (4,160,935,859.08) | (127,578,524,899.44) | (83,948,644.07) | (102,357,456.14) | (719,611.53) |
| Earnings per share, diluted‡ USD per share | (10,578,650,489.17) | (4,160,935,859.08) | (127,578,524,899.44) | (83,948,644.07) | (102,357,456.14) | (719,611.53) |
| Weighted average shares, basic‡ thousands of shares | 0 | 0 | 0 | 0 | 0 | 0 |
| Weighted average shares, diluted‡ thousands of shares | 0 | 0 | 0 | 0 | 0 | 0 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-33.33 stock split (September 2021); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-3.0303030303030303 stock split (September 2021); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-75.18796992481204 stock split (January 2023); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-59.880239520958085 stock split (May 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (March 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-35.714285714285715 stock split (June 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (April 2026); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-35.08771929824561 stock split (June 2026); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (JAGX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8,090 | 17,051 | 5,469 | 6,469 | 8,002 | 968 |
| Accounts receivable | 2,098 | 1,709 | 1,879 | 1,967 | 1,527 | 1,521 |
| Inventory | 2,782 | 4,900 | 7,024 | 9,189 | 10,345 | 8,599 |
| Prepaid and other current assets | 2,360 | 4,339 | 7,361 | 10,121 | 12,204 | 2,216 |
| Total current assets | 17,792 | 28,434 | 22,321 | 27,963 | 32,198 | 20,345 |
| Property and equipment, net | 677 | 650 | 557 | 496 | 464 | 463 |
| Right-of-use asset | — | 1,084 | 1,140 | 1,176 | 936 | 1,000 |
| Total assets | 42,843 | 53,265 | 47,452 | 50,763 | 53,425 | 38,323 |
| Accounts payable | 4,759 | 4,929 | 5,808 | 4,974 | 5,286 | 8,686 |
| Accrued liabilities | 4,493 | 7,117 | 8,165 | 3,798 | 1,911 | 4,166 |
| Total current liabilities | 13,220 | 15,471 | 30,339 | 13,987 | 19,704 | 40,654 |
| Lease liability, non-current | — | 919 | 725 | 886 | 686 | 892 |
| Total liabilities | 25,641 | 41,412 | 48,808 | 45,866 | 44,446 | 57,011 |
| Accumulated deficit | (166,899) | (219,494) | (266,948) | (308,248) | (346,482) | (399,916) |
| Total stockholders' equity | 17,202 | — | — | — | — | — |
| Total liabilities and equity | 42,843 | 53,265 | 47,452 | 50,763 | 53,425 | 38,323 |
Cash flows
CSVFiscal years (JAGX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (33,809) | (53) | (48) | (41,300) | (39) | (53,575) |
| Stock-based compensation | 2,824 | 3,974 | 3,318 | 2,112 | 1,641 | 831 |
| Depreciation and amortization | 1,727 | 1,719 | 1,981 | 2,013 | 1,900 | 1,913 |
| Net cash from operating activities | (15,278) | (34,970) | (33,104) | (33,242) | (29,384) | (23,686) |
| Purchases of property and equipment | 7 | 6 | 77 | — | 16 | — |
| Net cash from investing activities | (7) | (6) | (1,675) | — | (231) | (41) |
| Proceeds from long-term debt | 12,300 | — | — | — | — | — |
| Repayments of long-term debt | 406 | 100 | — | — | — | — |
| Net cash from financing activities | 19,492 | 43,937 | 23,181 | 34,227 | 31,202 | 23,670 |
| Net change in cash | 4,207 | 8,961 | (11,582) | 1,000 | 1,533 | (170) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Jaguar Health | 3,788 | 1,225 | (5,338)* | not reported | 0.7 quarters | 10-QJun 30, 2026 |
| Theriva Biologics | 11,337 | 0* | (3,085)* | 45.9M | 3.7 quarters | 10-QJun 30, 2026 |
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| China Pharma Holdings | 305 | 948 | (33)* | 43.0M | 9.3 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.